0001178697 2025-01-01 2025-12-31 0001178697 2025-06-30 0001178697 2026-04-21 iso4217:USD shares iso4217:USD shares true FY 0001178697 10-K/A true 2025-12-31 --12-31 2025 false 001-38907 DNA X, Inc. DE 94-3336783 4445 Eastgate Mall Suite 200 San Diego CA 92121 (661) 618-7580 Common Stock, par value $0.001 per share SONM NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 12600000 1488268 0.001 None. This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends DNA X, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 15, 2026 (the “Original Form 10-K”). We are filing this Amendment pursuant to General Instruction G(3) of Form 10-K, as we currently expect that our definitive proxy statement for the 2025 annual meeting of stockholders will be filed later than the 120th day after the end of the last fiscal year. Accordingly, this Amendment is being filed solely to:    ● amend Part III, Items 10, 11, 12, 13, and 14 of the Original Form 10-K to include the information required by and not included in such Items;         ● delete the reference on the cover of the Original Form 10-K to the incorporation by reference of certain information from our proxy statement into Part III of the Original Form 10-K;         ● Amend Part IV, Item 15 of Part IV of the Original Form 10-K to include in the Exhibits Index certain exhibits required to be listed in, but inadvertently excluded from, such Item; and       ● file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment under Item 15 of Part IV hereof pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, and to Section 302 of the Sarbanes-Oxley Act of 2002.   This Amendment does not otherwise change or update any of the disclosures set forth in the Original Form 10-K.   References to the “Company,” “DNA X,” “we,” or “our” in this Amendment refer to DNA X, Inc. and, as applicable, its wholly owned and consolidated subsidiaries. true